Other headlinesAccelaRAD extends client baseCarestream readies laser imager
MR maverick dodges Nasdaq bullet
Fonar has until Oct. 5 to prove to the Nasdaq exchange that the company has at least $500,000 in net income for the fiscal year ending June 30, 2009. The deadline was set by Nasdaq Listing and Hearing Review Council, which determined on June 24 that the maker of MR scanners can remain listed on the exchange until that time. Fonar has reported net income of more than $1 million for the first nine months of the current fiscal year.
AccelaRAD extends client base
IT network specialist AccelaRAD announced June 26 the installation of advanced digital management software at five new sites. Three are Mid-Atlantic Unified Health System-affiliated imaging centers, which are using AccelaRAD’s Virtual Radiology Network to provide PACS functionality, offsite archiving, and sophisticated online communication with referring physicians. The other two are using the network to provide remote access to images for offsite radiology reading groups.
Carestream readies laser imager
The FDA has cleared a tabletop laser imager from Carestream Health designed for digital mammography and general radiography. Shipments in the U.S. and other countries are set to begin immediately. The new laser imager, dubbed DRYVIEW 5850, offers 508 pixels-per-inch output. Two on-line film trays support DICOM printing of general radiography and mammography from both full-field digital and computed radiography systems.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.